Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Intangibles (2016 - 2025)

Gsk has reported Intangibles over the past 11 years, most recently at $22.3 billion for Q4 2025.

  • Quarterly results put Intangibles at $22.3 billion for Q4 2025, up 11.87% from a year ago — trailing twelve months through Dec 2025 was $22.3 billion (up 11.87% YoY), and the annual figure for FY2025 was $22.3 billion, up 11.87%.
  • Intangibles for Q4 2025 was $22.3 billion at Gsk, up from $19.9 billion in the prior quarter.
  • Over the last five years, Intangibles for GLAXF hit a ceiling of $40.5 billion in Q4 2021 and a floor of $16.8 billion in Q4 2022.
  • Median Intangibles over the past 5 years was $19.9 billion (2024), compared with a mean of $23.6 billion.
  • Biggest five-year swings in Intangibles: tumbled 58.58% in 2022 and later increased 11.87% in 2025.
  • Gsk's Intangibles stood at $40.5 billion in 2021, then tumbled by 58.58% to $16.8 billion in 2022, then increased by 9.14% to $18.3 billion in 2023, then rose by 8.64% to $19.9 billion in 2024, then rose by 11.87% to $22.3 billion in 2025.
  • The last three reported values for Intangibles were $22.3 billion (Q4 2025), $19.9 billion (Q4 2024), and $18.3 billion (Q4 2023) per Business Quant data.